

## German stem cell bank leading in storage technology

Vita 34 gets European patent on the preservation of umbilical cord tissue

***Leipzig, January 24, 2017. The European Patent Office has granted the stem cell bank Vita 34 the patent on the processing and cryo-preservation of umbilical cord tissue and the contained cells. It concerns a procedure of disinfecting, preparing, preserving, and isolating cells from umbilical cord tissue. The patent emphasizes the company's leading position and is an important basis of future medicine. Stem cells from umbilical cord tissue will play an important role in the individual treatment of many cartilage and joint diseases, in growing new tissue for regenerative medicine and even in growing new functioning organs.***

Implementing these advanced technologies requires stem cells from umbilical cord tissue that are prepared and stored in a professional and proper manner, so that cells capable of specialization and proliferation can develop into cartilage, bone, or even whole organs for the respective patient after years of preservation. Vita 34 is the only German stem cell bank allowed to store blood and tissue from the umbilical cord of newborns for later application according to the applicable regulations. With the European patent, the company confirms its role as leader in the research and development of medical procedures to play a crucial part regarding the health and prolongation of life in the future.

Dr. André Gerth, CEO of Vita 34 AG: "The issue of the patent is an acknowledgement that the investments into our research and development works are worth it. We are on the right track and continue our strategy of product development and strengthening our market leadership."

Vita 34 is the only stem cell bank in Germany permitted to store umbilical cord blood and tissue in line with Good Manufacturing Practice (GMP) guidelines. The company was able to increase the number of storages of umbilical cord tissue constantly since the product placement and thus to further strengthen the leadership on the important domestic market of Germany.

Vita 34 will continue to accelerate growth in the future by introducing new products and thus remain an innovation leader in Europe. Last year, the company was recognized as one of the hundred most innovative companies of German small and medium-sized businesses.

### Vita 34 AG

Your contact person:  
Dr. André Gerth (CEO)

Phone: +49 (0)341 48792-40

Fax: +49 (0)341 48792-39

Email: [andre.gerth@vita34.de](mailto:andre.gerth@vita34.de)

Web: [www.vita34.com](http://www.vita34.com)

Leipzig HRB 20339

Amtsgericht Leipzig

VAT No.

DE 239 733 620

Management Board:

Dr. André Gerth (Chairman)

Dr. W. Knirsch, Falk Neukirch

Chairman of the supervisory Board:

Dr. Hans-Georg Giering

Commerzbank

IBAN: DE57 8604 0000 0100 3334 00

BIC: COBADEFFXXX

## About Vita 34

*Vita 34 AG with headquarters in Leipzig is the largest and most experienced stem cell bank in the German-speaking countries. The company established in 1997, specializes in the storage of stem cells from umbilical cord blood and tissue for preventive medical care and the manufacture of stem cell transplants from umbilical cord blood. Currently, umbilical cord blood and tissue of about 145,000 children from Germany and other European and extra-European countries is stored. Vita 34 has proved the high quality of the previously cryo-preserved and stored stem cell preparations impressively by means of 30 applications already.*

### **Vita 34 AG**

Your contact person:  
Dr. André Gerth (CEO)

Phone: +49 (0)341 48792-40

Fax: +49 (0)341 48792-39

Email: [andre.gerth@vita34.de](mailto:andre.gerth@vita34.de)

Web: [www.vita34.com](http://www.vita34.com)

Leipzig HRB 20339

Amtsgericht Leipzig

VAT No.

DE 239 733 620

Management Board:

Dr. André Gerth (Chairman)

Dr. W. Knirsch, Falk Neukirch

Chairman of the supervisory Board:

Dr. Hans-Georg Giering

Commerzbank

IBAN: DE57 8604 0000 0100 3334 00

BIC: COBADEFFXXX